Dose-finding trial designs for combination therapies in oncology

Journal of Clinical Oncology

Volumn 32, Issue 2, 2014, Pages 65-67

  Mandrekar, Sumithra J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NERATINIB; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; DECISION MAKING; DOSE CALCULATION; DRUG SAFETY; EDITORIAL; HUMAN; MAXIMUM TOLERATED DOSE; MOLECULARLY TARGETED THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SOLID TUMOR; FEMALE; GENETICS; MALE; NEOPLASM; NOTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; NEOPLASMS; RECEPTOR, ERBB-2;

EID: 84894872013     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.9198     Document Type: Editorial

References (19)

1. Gandhi L, Bahleda R, Tolaney SM, et al: Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol 32:68-75, 2014
2. Ivanova A, Wang K: A non-parametric approach to the design and analysis of two-dimensional dose-finding trials. Stat Med 23:1861-1870, 2004 (Pubitemid 38787088)
3. Storer BE: Design and analysis of phase I clinical trials. Biometrics 45:925-937, 1989
4. Thall PF, Millikan RE, Mueller P, et al: Dose-finding with two agents in phase I oncology trials. Biometrics 59:487-496, 2003 (Pubitemid 37093387)
5. Conaway MR, Dunbar S, Peddada SD: Designs for single- or multiple-agent phase I trials. Biometrics 60:661-669, 2004 (Pubitemid 39181110)
6. Wang K, Ivanova A: Two-dimensional dose finding in discrete dose space. Biometrics 61:217-222, 2005 (Pubitemid 40380982)
7. Hamberg P, Ratain MJ, Lesaffre E, et al: Dose-escalation models for combination phase I trials in oncology. Eur J Cancer 46:2870-2878, 2010
8. Simon R, Korn EL: Selecting combinations of chemotherapeutic drugs to maximize dose intensity. J Biopharm Stat 247-258, 1991
9. Yin G, Yuan Y: Bayesian dose-finding in oncology for drug combinations by copula regression. J R Stat Soc: Series C (Applied Statistics) 58:211-224, 2009
10. Dykstra R, Robertson T: An algorithm for isotonic regression for two or more independent variables. Ann Stat 10:708-716, 1982
11. O'Quigley J, Pepe M, Fisher L: Continual reassessment method: A practical design for phase 1 clinical trials in cancer. Biometrics 46:33-48, 1990 (Pubitemid 20245604)
12. Shen LZ, O'Quigley J: Consistency of continual reassessment method under model misspecification. Biometrika 83:395-405, 1996
13. Rogatko A, Schoeneck D, Jonas W, et al: Translation of innovative designs into phase I trials. J Clin Oncol 25:4982-4986, 2007 (Pubitemid 350220431)
14. Mandrekar SJ, Qin R, Sargent DJ: Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: Methods and challenges. Stat Med 29:1077-1083, 2010
15. Mandrekar SJ, Sargent DJ: CRM trials for assessing toxicity and efficacy, in John Crowley, Antje Hoering: Handbook of Statistics in Clinical Oncology (ed 3). Boca Raton, FL, CRC Press, 2012, pp 85-96
16. Huang X, Biswas S, Oki Y, et al: A parallel phase I/II clinical trial design for combination therapies. Biometrics 63:429-436, 2007
17. Dragalin V, Fedorov VV, Wu Y: Adaptive designs for selecting drug combinations based on efficacy-toxicity response. J Stat Plan Inference 138:352-373, 2008
18. Mandrekar SJ, Cui Y, Sargent DJ: An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations. Stat Med 26:2317-2330, 2007 (Pubitemid 46730251)
19. Zohar S, Chevret S: Recent developments in adaptive designs for Phase I/II dose-finding studies. J Biopharm Stat 17:1071-1083, 2007 (Pubitemid 350135835)